Medicus Pharma Ltd (MDCX)
NASDAQ:MDCX
Want to see MDCX full AI Analyst Report?
MDCX Stock Chart & Stats
$1.46
-$0.29(-9.70%)
At close: 4:00 PM EST
$1.46
-$0.29(-9.70%)
Day’s Range― - ―
52-Week Range$0.25 - $3.69
Previous CloseN/A
Volume5.92K
Average Volume (3M)2.48M
Market Cap
$25.92M
Enterprise Value$1.56M
Total Cash (Recent Filing)$6.37M
Total Debt (Recent Filing)$169.62K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 20, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding56,658,165
10 Day Avg. Volume2,189,213
30 Day Avg. Volume2,484,235
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-391.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$5.50Price Target Upside276.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Progress: Rare Pediatric Designation FilingFiling for Rare Pediatric Disease Designation is a structural regulatory milestone that can expedite development pathways and unlock incentives (e.g., priority review or vouchers). This advances SkinJect toward a clearer approval path and improves program de-risking over the next months.
Advancing Teverelix Toward Registrational Phase 2bA formal EU CTIS submission for a Phase 2b registrational-focused study reflects strategic progression from exploratory to registrational development. This structural step refines dose/PK/PD data and strengthens the program’s regulatory dossier for future approval-enabling trials.
Modest Reported Leverage And Asset GrowthCurrent reported leverage is low on a TTM basis, and asset growth signals capacity to build program infrastructure. Modest leverage reduces short-term solvency risk and, when combined with capital access, supports continued clinical execution over the medium term.
Bears Say
Pre-revenue With Widening LossesThe company remains pre-revenue while operating losses have expanded materially. Persistent negative earnings reflect no internal revenue runway and create ongoing pressure to fund development externally, increasing long-term dilution and execution risk if trials delay.
Large, Sustained Cash Burn And Negative FCFSubstantial negative operating and free cash flow indicate the company cannot self-fund development. This structural cash burn necessitates repeated external financing, constrains strategic choices, and elevates the probability of dilution or compromised program timelines.
Nasdaq Non-compliance And Dilutive Funding RelianceAn active Nasdaq non-compliance notice plus expansion of ATM capacity signals structural listing and liquidity pressure. Management faces persistent incentive to raise equity, increasing dilution risk and potentially impairing investor confidence and long-term capital access.
Medicus Pharma Ltd News
MDCX FAQ
What was Medicus Pharma Ltd’s price range in the past 12 months?
Medicus Pharma Ltd lowest stock price was $0.25 and its highest was $3.69 in the past 12 months.
What is Medicus Pharma Ltd’s market cap?
Medicus Pharma Ltd’s market cap is $25.92M.
When is Medicus Pharma Ltd’s upcoming earnings report date?
Medicus Pharma Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 60 days.
How were Medicus Pharma Ltd’s earnings last quarter?
Medicus Pharma Ltd released its earnings results on May 14, 2026. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.118.
Is Medicus Pharma Ltd overvalued?
According to Wall Street analysts Medicus Pharma Ltd’s price is currently Undervalued.
Does Medicus Pharma Ltd pay dividends?
Medicus Pharma Ltd does not currently pay dividends.
What is Medicus Pharma Ltd’s EPS estimate?
Medicus Pharma Ltd’s EPS estimate is -0.13.
How many shares outstanding does Medicus Pharma Ltd have?
Medicus Pharma Ltd has 56,658,165 shares outstanding.
What happened to Medicus Pharma Ltd’s price movement after its last earnings report?
Medicus Pharma Ltd reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went down -10.682%.
Which hedge fund is a major shareholder of Medicus Pharma Ltd?
Currently, no hedge funds are holding shares in MDCX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicus Pharma Ltd
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
MDCX Stock 12 Month Forecast
Average Price Target
$5.50
▲(276.71% Upside)
Technical Analysis
Ovid Therapeutics
―
Jasper Therapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
0.48% Insiders
<0.01% Mutual Funds
3.11% Other Institutional Investors
96.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---